Form 4: Collegium Pharma GC Boosts Stake with RSU Grant, PSU Vesting

Collegium Pharmaceutical's EVP & General Counsel, David Dieter, increased his beneficial ownership through a significant restricted stock unit grant and performance share unit vesting.

Summary

• David Dieter, EVP & General Counsel of Collegium Pharmaceutical, Inc. (COLL), reported transactions on February 10, 2026.
• He was granted 22,194 Restricted Stock Units (RSUs), each representing a contingent right to one share of common stock, vesting one-third on February 10, 2027, and the remainder in equal annual installments over the subsequent two years.
• An additional 9,005 Performance Share Units (PSUs) from the 2025 fiscal year vested, as performance criteria were met.
• To cover applicable withholding taxes upon PSU vesting, 2,781 shares were disposed of by the Issuer at a price of $46.75 per share.
• Following these transactions, David Dieter's beneficial ownership stands at 97,271 shares of common stock.
• His beneficial ownership also includes 404 shares acquired on January 16, 2026, through the Issuer's employee stock purchase plan.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal. The executive's increased equity stake through grants and vesting aligns interests with shareholders, and the PSU vesting indicates successful performance against prior targets.

Positives

• Grant of 22,194 Restricted Stock Units (RSUs) to a key executive, aligning his interests with shareholders.
• Successful vesting of 9,005 Performance Share Units (PSUs), indicating the achievement of performance criteria for the 2025 fiscal year.
• Acquisition of 404 shares through the employee stock purchase plan, demonstrating continued executive investment in the company.

Negatives

• Disposition of 2,781 shares at $46.75 to cover tax obligations upon PSU vesting, which reduces the executive's direct shareholding.

Future Outlook

The RSU grant includes a vesting schedule extending over the next three years, with the first third vesting on February 10, 2027, and the remainder in equal annual installments thereafter, contingent on continued service.

Industry Context

StockSavvy.ai notes that executive compensation through equity awards like RSUs and PSUs is a common practice in the pharmaceutical industry, aligning executive incentives with long-term shareholder value. The vesting of PSUs suggests the company met specific performance targets, which is generally a positive indicator for operational execution within the competitive pharma landscape.

Related Party Transactions

• Grant of 22,194 Restricted Stock Units (RSUs) by Collegium Pharmaceutical, Inc. to its EVP & General Counsel, David Dieter.
• Vesting of 9,005 Performance Share Units (PSUs) by Collegium Pharmaceutical, Inc. for David Dieter.
• Disposition of 2,781 shares by the Issuer on behalf of David Dieter to satisfy tax withholding obligations upon PSU vesting.

Stakeholder Impact

• Shareholders: Increased alignment of executive interests with shareholder value through equity awards. The vesting of PSUs suggests the company met performance targets, which could be positive for shareholder returns.
• Employees: The employee stock purchase plan (ESPP) mentioned for 404 shares indicates a broader program that benefits employees.
• Management: David Dieter's compensation package is enhanced, providing long-term incentives.

Next Steps

• One-third of the granted RSUs will vest on February 10, 2027.
• The balance of the RSUs will vest in equal annual installments over the two-year period following the initial vesting date.

Key Dates

Recommendation

While the executive's increased equity stake and the vesting of performance-based awards are positive signals, a Form 4 filing primarily details insider transactions and does not provide sufficient comprehensive financial or strategic information to warrant a 'buy' or 'sell' recommendation. It reinforces a 'hold' stance, acknowledging positive internal developments without suggesting a change in investment thesis based solely on this report.

Keywords

Collegium Pharmaceutical, COLL, Form 4, Insider Trading, Restricted Stock Units, RSUs, Performance Share Units, PSUs, Executive Compensation, Stock Grant, Vesting, David Dieter